Re: Trans-catheter versus open surgical aortic valve replacement in severe symptomatic aortic stenosis Authors: Ercan Keleş, Ömer Faruk Rahman Published: 2026 Dear Editor, We read with great interest the article by Mohammed Fawzy Eltaweel and colleagues entitled “Trans-catheter versus open surgical aortic valve replacement in severe symptomatic aortic stenosis” [1]. Comparing transcatheter aortic valve replacement (TAVR), whose indications have progressively expanded in recent years, with surgical aortic valve replacement (SAVR), which has well-established long-term durability, is clinically valuable, particularly when quality-of-life outcomes are evaluated alongside echocardiographic parameters such as effective orifice area (EOA). Nevertheless, several methodological and interpretative issues merit further discussion. First, the age profile of the TAVR cohort is noteworthy. The reported mean age of 54.58 years is considerably younger than that of the population for whom TAVR is traditionally recommended [2]. Although current guidelines increasingly support TAVR in selected younger patients, SAVR—particularly mechanical valve replacement—remains the preferred strategy in many relatively young individuals because of its proven durability. In this context, bioprosthetic degeneration and the need for future reintervention remain important concerns. Therefore, a more detailed explanation of the clinical rationale for TAVR selection in this relatively young cohort would improve the study’s interpretability and external validity. Although the authors report that patients were randomized into the two treatment groups, contemporary treatment selection for severe aortic stenosis is typically guided by multidisciplinary Heart Team assessment. Therefore, a more detailed description of the randomization process and allocation methodology would help readers better understand how these groups were established and further strengthen the study’s methodological transparency. Given that contemporary valve interventions are generally individualized through multidisciplinary Heart Team discussions, additional clarification regarding how computer-based randomization was integrated into routine clinical decision-making would be valuable. Another point deserving attention is the observation that quality-of-life outcomes were comparable between the TAVR and SAVR groups despite the greater invasiveness of surgery. Rather than suggesting superiority of either treatment strategy, these findings support the importance of individualized therapeutic decision-making, taking into account patient age, comorbidities, anatomical characteristics, and long-term valve durability. Although EOA was assessed, the absence of an indexed effective orifice area (iEOA) analysis is an important limitation. iEOA is a key parameter for evaluating prosthesis–patient mismatch (PPM), with direct implications for postoperative hemodynamics and quality of life. Because body surface area (BSA) data were not reported, iEOA could not be calculated, preventing adequate assessment of potential PPM and its clinical consequences. Recent studies have further emphasized the importance of iEOA-based evaluation after aortic valve replacement [3, 4]. In addition, the distribution of prosthetic valve types within the SAVR group was not clearly specified. The choice between mechanical and bioprosthetic valves is clinically relevant because prosthesis selection, lifelong anticoagulation requirements, and rhythm-related comorbidities such as atrial fibrillation may substantially influence symptom burden, postoperative management, and patient-reported quality-of-life outcomes [5]. The absence of a detailed analysis of these variables further complicates the interpretation of the reported quality-of-life comparisons. In conclusion, we believe the authors addressed an important and contemporary clinical issue. However, the reported randomization process, patient selection methodology, the applicability of TAVR in a relatively young population, the absence of iEOA/PPM assessment, and several unreported clinically relevant variables warrant cautious interpretation of the findings [2, 3]. Sincerely, Ercan Keles, MD. Omer Faruk Rahman, MD.